Precancerous Cervical Lesions: Screening, Diagnosis and Clinical Practice

Dear Colleagues,

The risk stratification of precancerous cervical lesions is a complex field of research that is undergoing constant improvement. With the introduction of multiple new and promising screening and diagnostic tests, we are now able to offer women an individualized risk profile and therapeutic management. There are multiple aims of this type of risk stratification, including the patients’ selection for colposcopy and cervical biopsy, choosing the best clinical conduct between follow-up and conservative cervical intervention, predicting the risk of residual lesions after conservative surgical management, and choosing the appropriate follow-up or surgical plans for such patients.

In order to fulfill these purposes, clinicians can use cytology and immunocytochemistry (Ki67, p16INK4a, p16/Ki-67 dual staining, ProExC including TOP2A (topoisomerase II α), MCM2 (minichromosome maintenance protein 2 expression) and other markers) or cell-block immunostaining, human papillomavirus (HPV) genotyping, cervical or vaginal microbiota, epigenomics, or specific markers (host cell gene metilation and molecular markers,) among other methods. Moreover, the inclusion of machine learning algorithms and artificial neural networks can improve the process of risk stratification by analyzing a large amount of complex data. This Special Issue on “Precancerous Cervical Lesions: Screening, Diagnosis and Clinical Practice” considers original research articles, review articles, commentaries and perspectives from all areas of precancerous cervical lesions research, risk stratification, and prediction.

Prof. Dr. Demetra Gabriela Socolov
Prof. Dr. Liana Pleş
Dr. Raluca Balan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cervical precancer
• colposcopy
• cervical cancer screening
• risk stratification
• HPV
• vaginal microbiota
• methylation markers
• immunocytochemistry
• artificial intelligence in colposcopy